Raol Nikhila, Metry Denise, Edmonds Joseph, Chandy Binoy, Sulek Marcelle, Larrier Deidre
Department of Otolaryngology, Texas Children's Hospital, Houston, TX, United States.
Int J Pediatr Otorhinolaryngol. 2011 Dec;75(12):1510-4. doi: 10.1016/j.ijporl.2011.08.017. Epub 2011 Sep 23.
Infantile subglottic hemangiomas are rare causes of airway obstruction. They begin to proliferate at 1-2 months of age and can cause biphasic stridor with or without respiratory distress. Diagnosis requires direct visualization by direct laryngoscopy and bronchoscopy. Various therapeutic options have been utilized for treatment, including tracheotomy, open surgical excision, laser ablation, intralesional steroid injection, systemic steroids, and now oral propranolol.
We present a retrospective chart review of infantile subglottic hemangiomas over a 5-year span (January 2005-2010) at a tertiary care pediatric hospital. IRB approval was obtained, and charts were reviewed to find patients with subglottic hemangiomas, including patient characteristics, presentation, workup, medical and surgical management, and outcomes. A case presentation demonstrates diagnostic, management, and treatment strategies and dilemmas encountered.
Nine patients were found to have infantile subglottic hemangiomas. Six of nine patients were treated with laser excision, with five of the six having localized subglottic hemangiomas. In 2009, three of four patients were initiated on propranolol as first-line treatment; the fourth had comorbidities which precluded this. Of the three, two showed improvement, while a third, who also had bearded hemangioma, required tracheotomy.
Infantile subglottic hemangiomas are rare but essential in the differential diagnosis of biphasic stridor. Although propranolol has been effective in treating cutaneous and airway hemangiomas, our experience suggests that this is not consistent for subglottic hemangiomas. In an area where airway compromise can be lethal, we must extend caution and monitor these patients closely as they may require adjuvant therapy.
婴儿声门下血管瘤是气道梗阻的罕见病因。它们在1至2个月大时开始增殖,可导致伴有或不伴有呼吸窘迫的双相性喘鸣。诊断需要通过直接喉镜和支气管镜进行直视检查。已经采用了多种治疗方法,包括气管切开术、开放性手术切除、激光消融、瘤内类固醇注射、全身用类固醇,以及现在的口服普萘洛尔。
我们对一家三级儿科医院5年期间(2005年1月至2010年)的婴儿声门下血管瘤进行了回顾性病历审查。获得了机构审查委员会的批准,并审查病历以查找声门下血管瘤患者,包括患者特征、临床表现、检查、药物和手术治疗以及治疗结果。一个病例展示了所遇到的诊断、管理和治疗策略及困境。
发现9例患者患有婴儿声门下血管瘤。9例患者中有6例接受了激光切除治疗,其中6例中的5例患有局限性声门下血管瘤。2009年,4例患者中有3例开始使用普萘洛尔作为一线治疗;第4例患者有合并症,不适合使用。在这3例患者中,2例病情改善,而第3例同时患有须状血管瘤,需要进行气管切开术。
婴儿声门下血管瘤虽罕见,但在双相性喘鸣的鉴别诊断中至关重要。尽管普萘洛尔在治疗皮肤和气道血管瘤方面有效,但我们的经验表明,对于声门下血管瘤并非如此。在气道受损可能致命的情况下,我们必须谨慎行事,并密切监测这些患者,因为他们可能需要辅助治疗。